IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

A Review: Excessive use of antacid can cause kidney injury

Shital. R. Chaudhari*, Shubham. D. Chaudhari, Tejas. R. Chaudhari, Mayur. A. Chaudhari, Tushar. A. Deshmukh

SES Arunamai College of Pharmacy Mamurabad, Jalgaon. Maharashtra 425002

Abstract:

In most cases, proton pump inhibitors (PPIs) are approved for the treatment of a variety of digestive issues brought on by overeating. Although compelling and safe, kidney expansion impacts have been portrayed. Most concerning is the consistent expansion in the quantity of instances of intense interstitial nephritis (AIN) related with proton siphon inhibitor treatment. It has every one of the qualities of a class impact, as all proton siphon inhibitors have been accounted for to cause AIN. Proton pump inhibitors (PPIs) are currently the most common cause of drug-induced AIN, according to numerous adverse drug case registries. Most patients' parents were able to regain kidney function, but many still had some form of persistent kidney infection. Hyponatremia is a fascinating inconvenience remembered to be because of deficient emission of ADH. When used in patients with impotence, some proton pump inhibitors and calcineurin inhibitors can be combined, particularly in patients with a polymorphism in the cytochrome P4502C19 complex. This article will basically investigate the impact of proton siphon inhibitors on the kidneys.

Keywords: Antacid, acute kidney injury, Chronic kidney injury, Over the counter

Introduction:

Stomach-settling specialists are the get-together of meds that have been accessible for quite a while. They were the first line of defense against peptic ulcer disease, but the discovery of proton siphon inhibitors changed how peptic ulcer disease is treated. [1] This is exactly what has been demonstrated for the majority of subsequent applications of acid neutralizers. Late examinations have recommended that consuming acridity medications regularly could provoke long haul kidney hurt, serious renal ailment and consistent kidney contamination. Stomach settling specialists are over the counter (OTC) drugs that assist with killing stomach corrosives. Corrosive neutralizers can be used to treat the results of a wealth of stomach destructive, for instance,

- Heartburn, which can consolidate vomiting, unforgiving taste, consistent dry hack, torture when
- Resting, and burden swallowing
- Heartburn, which is a consuming sensation in your chest or throat achieved by indigestion
- Heartburn, which is torture in your upper stomach that can feel like gas or enlarging. [2]

One particle of the medication known as a stomach-settling agent is included in each substitute remedy prescribed by enrolled medical professionals. Nevertheless, uncontrolled use of corrosive neutralizers having a spot with

'Proton Siphon Inhibitors' (PPIs) has extended 'Extraordinary Kidney Damage' in patients. In light of this problem, the Drug Control Regulator General of India (DCGI), V G Somani, has instructed the state controllers to ask pharmaceutical companies that make proton siphon inhibitors to include "intense kidney injury" as an unfriendly drug response on medication packs' understanding data pamphlets. DCGI has now requested that drug associations alert patients about the bet of kidney hurt on the packaging of explicit corrosive neutralizers.

Antacid:

Heartburn and indigestion are both treated with medications known as stomach settling agents. You can get stomach-settling specialists over the counter without a cure. Destructiveness started being treated with the help of corrosive neutralizers in the year 1970. Stomach settling specialists work quickly to lessen how much destructive in your stomach to ease the aftereffects. Stomach-settling specialists kill the destructive in your stomach by ending a protein that makes it destructive to isolate sustenance for retention (pepsin). The Food and Medicine Association supported stomach-settling specialists for treating delicate examples of indigestion and acid reflux. They contain trimmings like aluminum, calcium, magnesium, or sodium bicarbonate which go about as bases (salts) to check stomach destructive and make its pH more unprejudiced. Stomach-settling specialists are available as liquids or tablets. Alginates or a combination of several stomach-settling agent fixings are present in some products. Alginates are substances that resemble gum and float on top of stomach contents, forming an obstruction-like pontoon. These may outfit more aftereffect easing in people with reflux. A couple of things similarly contain various trimmings that are not stomach-settling specialists or alginates, for instance, simethicone which disperses gas in people leaned to protruding. Migraine medication similarly incorporates a few things (for example Alka-Seltzer). Stomach-settling specialists moreover curb pepsin, which is a compound that plays a task in protein handling. Pepsin works with hydrochloric destructive in the stomach to give the acidic environment critical to handle food. Corrosive neutralizers work quickly to ease aftereffects for scarcely any hours. The side effects of stomach-settling agents are not treated. [4]

What is a Kidney injury?

Kidney injury suggests mischief or impedance of the kidneys' plan or capacity, which can prompt a decline in kidney ability and conceivably serious unforeseen issues. Kidney injury can result from various causes, including illnesses, remedies, harms, and actual injury.

- **Acute Kidney Injury (AKI):**

AKI, as of late known as serious renal disillusionment, is a surprising start of kidney brokenness depicted by a quick diminishing in kidney capacity over hours to days. Dryness, serious infections, kidney diseases (pyelonephritis), urinary tract obstruction, decreased blood flow to the kidneys (hypo perfusion), and nephrotoxic medications or other substances are typical causes of AKI

- **Chronic Kidney injury (CKI):**

CKD is depicted by a sluggish loss of kidney capacity over months to years, provoking irreversible damage and a moderate decline in kidney capacity. Diabetes, hypertension, glomerulonephritis, polycystic kidney disease, immune system diseases, and delayed exposure to nephrotoxic specialists are typical risk factors for CKD. [5]

Classification of antacid:



Chart: The classification of antacid. [6]

Types of antacid:

Different kinds of corrosive neutralizers are open. Some are marketed under a brand name, while others are referred to by the primary fixing, they contain. Brands consolidate Gaviscon (alginic destructive) and Pepto-Bismol (bismuth subsalicylate). The fixes to look for include. This table describes various arrangements of stomach-settling specialists: [7]

	Calcium	Sodium	Magnesium	Aluminium
Species	Carbonate	Bicarbonate, citrate	Hydroxide, carbonate, oxide, trisilicate	Hydroxide, carbonate, phosphate, glycinate
Category	Non-absorbable	Absorbable	Non-absorbable	Non-absorbable
ANC (m Eq/15 mL) c	58	17	35	29
Maximum daily dosage limit (m Eq) d	160	200 60 years old) and 100 (>60 years or older)	50	NA
Limitations	Constipation and flatulence Systemic alkalosis and hypercalcemia on long term use Occasional milk-alkali syndrome in patients taking more than the recommended dose	Non-serious, stomach/gut irritations that could cause gas or bloating	Dose-related diarrhea Flushing Hypotension Vasodilation Hypermagnesemia	Hypomagnesemia Hypophosphatemia Constipation Anaemia
FDA category for antacid use in pregnancy	None	None	None	None
Contraindications Renal	No	Yes	Yes	Yes
impairment				
Hepatic impairment	No	Yes	No	No

Allergy to the antacid ingredient(s) in the formulation	Yes	Yes	Yes	Yes
Others	Patients with hypercalcemia, hypercalciuria, nephrocalcinoses and nephrolithiasis Patients on a low phosphate diet	Patients on a sodium-restricted diet, e.g.., those with hypertension or congestive heart failure	Patients with severe diarrhea Patients with neuromuscular disease such as myasthenia gravis	Patients with constipation

Table 1: Features and limitations of different types of antacid salts. [8, 9, 10, 11]

Therapeutic uses of antacid:

Corrosive neutralizers can be used to facilitate the going with secondary effects:

- A consuming tendency in your chest or stomach, particularly directly following eating or around nighttime
- An acidic or cruel longing for your mouth
- Feeling expanded or full
- Not exactly overpowering torture in your chest and stomach.

Stomach-settling specialists have a supportive requirement for the going with:

- GERD side effects of acid reflux
- Duodenal and gastric ulcers
- Stress gastritis
- Pancreatic lack
- Dyspepsia without ulcer
- Bowel looseness brought on by bile-corrosive
- Biliary reflux
- Check
- Osteoporosis
- Alkalinization of urine
- Phosphate restriction in persistent renal failure. [12]

Causative agents:

- Pregnancy
- OTC

- Drug interactions
- Low magnesium
- Defilement
- Inherited factors
- Hypertension
- Safe framework disease

Side effects of antacids:

- Check or the runs.
- Gas (honking).
- Headache.
- Squeamishness and regurgitating.

Stomach issues or torture in the midriff. Serious auxiliary impacts could include:

- Destructive return: Stomach settling specialists make your body produce more destructive, which break down
- Neurotoxicity: A corrosive neutralizer changes the ability of your tactile framework.
- Microcytic shortcoming: Iron deficiency.
- Osteopenia: bones that are weak.
- Hypercalcemia: A high blood calcium level. [4]

Gastric acid secretion inhibitors:

In this regard, the group consisting of proton pump inhibitors and gastric corrosive emission inhibitors (GEIs) is the one that is responsible for the greatest amount of kidney damage in comparison to the following:

a) **H_2 Antihistamine**:

Receptor H2-receptor miscreants, generally called H2-blockers, are used to treat duodenal ulcers besides hindering their return. They are moreover used to treat gastric ulcers and for specific conditions, for example, Zollinger-Ellison's ailment, in which the stomach makes an overabundance of destructive. In over the counter (OTC) characteristics, these drugs are used to soothe or possibly thwart heartburn, destructive acid reflux, likewise, sharp stomach. [6]

Brand name: Zantac, Pepcid

Mechanism of action:



Dig 1: Mechanism of action of H2 antihistamine

H2RAs decline gastric destructive emanation by reversibly confining to receptor H2 receptors tracked down on gastric parietal cells, in this way controlling the restricting and development of the endogenous ligand-receptor. As a result, H2 blockers can function as serious adversaries. Routinely, after supper, gastrin varies receptor release from enteron chromaffin-like cells, which then binds to receptor H2 receptors on gastric parietal cells and prompts gastric destructive conveyance. This development in gastric destructive release occurs through the activation of adenylate cyclase, which raises intracellular CAMP levels. CAMP then, at that point, starts protein kinase A (PKA), which, among various capacities, phosphorylates proteins related with the improvement of H+/K+ ATPase transporters to the plasma film. The addition of H+/K+ ATPase transporters at the plasma film considers the outflow of more destructive from parietal cells.[13] By hindering the receptor and thusly receptor sensation of parietal cell destructive release, H2RAs cover both animated and basal gastric destructive release incited by the receptor. The start of gastric assistance given by H2RAs is about an hour with a term of movement that scopes from 4 to 10 hours, making them significant for the on-demand treatment of coincidental incidental effects. All H2RAs have tantamount ampleness in decreasing gastric destructive emanation. [14]

Effect of H2 Antihistamine on Kidney:

The above examination can be used to extrapolate the role that receptors play in renal disease. Plus, the overall responsibility of every receptor reflects their scattering, with the receptor setting off both degenerative glomerular and adjusted changes through different receptor pathways. The perception that, in contrast to healthy subjects, plasma receptor levels are fundamentally higher in patients with nephrotic conditions, end-stage renal failure, and going through hemodialysis or peritoneal dialysis than in healthy subjects' High plasma receptor levels is the source of the connection between receptor and renal disease in people. This data is consistent with the receptor's ability to diminish urea opportunity. Receptors may

in this manner antagonistically influence renal ability. This theory is maintained by a couple of in vivo focuses on nitty gritty. Regardless, the occupation of receptor in renal diseases can similarly be guessed similarly as the presence of post cells in a couple of kidney sicknesses with a prominent fibrotic part. The presence of pole cells is related to the dynamic loss of renal capacity, regardless of the hidden illness. An extension in shaft cells was found to look like renal ability in fundamental and helper sorts of membranous, diabetic, and IgA nephropathy and in allograft excusal as well as in amyloidosis, renovascular ischemia, reflux nephropathy, polycystic kidney ailment, and drug-induced nephropathy. The restriction of shaft cells has besides been proposed as a likely levelheaded in tubulointerstitial fibrosis. TGF, among other well-known profibrotic middle people, is released by pole cells.

Drug	**Mode OF Action**	**Delivery**	**Renal Effect**
Ranitidine	Blocker	Fed at 1.5 mg/ 30 g Body weight.	Reduced renal damage and attenuated atherosclerosis in a HFD mouse model.
Cimetidine	Antagonist	IP Injection Of 150 mg/kg 0.25-1.2 mM additional to cell-free.	Decreased creatinine, BUN, K+, Na+, NO, blood pressure creatine Kinase, increased GFR, urine volume and renal.
		extract	glutathione; improved renal function when used in combination with L-carnitine in a rat model of glycerol induced acute renal failure.
Famotidine	Antagonist	Intraperitoneal Injection [20 mg/kg].	Reduced blood levels of IL-6. IL-16. And TNF-a. reduced tissue levels of IL- 1B, IL-6. and TNF-c MRNAs.

Table 2: Pharmacology targeting histamine receptors and their combinations; reported are the drugs known to affect renal system function

Proton pump inhibitors (PPIs):

Any medicine that covers the emanation of gastric destructive by impeding a protein in the parietal cells of the stomach that exchanges destructive for potassium particles. The Proton siphon inhibitors are used in the treatment of erosive esophagitis and peptic ulcer. Exactly when given in sufficient portion, these prescriptions can reduce destructive outflow by more than 95%. Occasions of proton siphon inhibitors consolidate omeprazole, lansoprazole, and rabeprazole. Yet fruitful in specific patients, the long usage of

proton siphon inhibitors relates to perhaps serious auxiliary impacts, including the extended opportunity of abrupt passing and the improvement of stomach harmful development, persevering kidney contamination, and cardiovascular disorder. [6]

Effect of PPIs on Kidney:

Kidney infection is one of the most dangerous side effects of taking PPI medications. Review have shown that long PPI clients are practically 100% than patients taking H2 blockers (another class of indigestion drugs) to cultivate issues with their kidneys, including kidney mischief and kidney dissatisfaction. "Proton siphon inhibitors can really hurt kidney in two designs. One is extraordinary kidney injury, called extreme interstitial nephritis, which in layman's terms looks like an overly sensitive reaction to the prescription. It isn't extraordinarily considered common, in any case, it ends up working. The other is progressing kidney injury, which is achieved by postponed usage of the drug. A deliberate review and meta-examination summarized these effects into four enormous outcomes: AIN, AKI, CKD, and end-stage renal infection (ESRD). The essential saw connection between AIN and PPIs was made in 1992. Nowadays, PPIs are seen as one of the most notable explanations behind drug-impelled AIN. An inevitable friend examination found that PPI usage is a free bet factor for CKD and AKI. Inquisitively, a survey case-control focuses on communicating that more energetic patients will undoubtedly encourage CKD. One more sidekick focused on said it is more typical for additional laid out patients to cultivate AKI and AIN connected with PPI use. CKD patients who ought to be treated with PPIs should be under creatinine-level noticing.

c) Gastric acid Neutralizers:

Generally, when a human faces overproduction of acids, it causes irritating in the stomach. The working of the stomach incorporates the discharge of hydrochloric destructive during osmosis. The overproduction of hydrochloric destructive causes aggravation and torture in the stomach. Additionally, this could result in stomach ulcers.

Antacids are classified into two categories

- Systemic (absorbable) antacids.
- Non-systemic (non-absorbable) antacids.

Non systemic	Systemic

• Non-systemic antacids that are not absorbed into the systemic circulation. • Their anionic group neutralizes the H+ ion in gastric acid. These release their cationic group which combines with HCO-3 from the pancreas to form an insoluble basic compound that is excreted in faces. • Thus, these agents do not produce metabolic alkalosis	• Systemic antacids are absorbed into the systemic circulation. • They have a cationic group that does not form insoluble basic compound with HCO3-. • Thus, HCO3 can be absorbed producing a metabolic alkalosis
Example	**Example**
• Aluminium hydroxide • Magnesium hydroxide	• Sodium bicarbonate. • Sodium citrate.

Most used antacid which causes kidney injury:

PPIs are irrefutably the most used calms all over the planet. A couple of investigations have shown the linkage between long stretch use of PPIs and steady kidney disease (CKD) - one survey that concentrated on more than 10,000 people saw that there was a 20-half higher bet of CKD in individuals who were using PPIs. It has similarly been associated with a higher bet of extreme interstitial nephritis (AIN) and end-stage renal disease, according to a couple of examinations. These assessments exhibit the way that diligent and deferred usage of PPIs can dangerously influence the renal system (kidneys).

Proton pump Inhibitors [PPI's]:

PPI frustrates the release of H+ particles from parietal cells in stomach related verdure and, in this way declines the improvement of destructive. Because of the last step impediment in gastric destructive release regardless of what the destructive release redesign, PPIs gained popularity and can be dosed once a day in numerous patients. Proton siphon inhibitors (PPIs) are by and large used for destructive camouflage treatment all around the planet. They are normally suggested for a couple of destructive related wrecks, including gastroesophageal reflux disorder (GERD), peptic ulcer sickness, esophagitis, gastritis, Barrett throat, and (in extension to hostile to microbial) Helicobacter pylori obliteration. Additionally, they are frequently recommended in conjunction with nonsteroidal anti-inflammatory drugs (NSAIDs) for the prevention of symptoms.

Available proton pump inhibitors include:

- Omeprazole (Prilosec, Prilosec OTC)
- Aspirin and omeprazole (Yosprala)
- Lansoprazole (Prevacid, Prevacid 24-Hour)
- Dex lansoprazole Prevacid IV, (Dexilant, DexilentSolutab)
- Rabeprazole (Aciphex, Aciphex Sprinkle)

- Pantoprazole (Protonix)
- Esomeprazole (Nexium, Nexium 24 HR) Nexium
- Esomeprazole magnesium/Naproxen (Vimovo) IV,
- Omeprazole/Sodium bicarbonate (Zeger\id, Zegerid OT
- Abdominal pain, Flatulence, Fever, Vomiting, Nausea, Rash. [15]

Mechanism of action:

The essential proton siphon inhibitor used clinically was 2 [(3, 5-dimethyl-4-methoxypyridin-2-yl) sulfinyl]-5-methoxy-1H-benzimidazole, omeprazole. This compound is a weak base ~pka 4. The parietal cells H+, K+-ATPase secrete corrosive into the secretory canaliculus, resulting in a lumen pH below 1.0. The acidity of this space makes it possible for the fragile Digestion: bases of this pka to accumulate. [16, 17, 18] Emanations with pka under 4.0 can be amassed only in this acidic space and can't in a few different spaces in the body. Then, this compound is immediately incited by the high destructiveness by confining to the cysteines that are accessible to the started structure provoking stifle destructive discharge. The restricting objections of omeprazole are Cys813 and Cys892. Other covalent limiting inhibitors having a spot with the subbed benzimidazole family were followed, Lansoprazole answers with Cys813 and Cys321, these being in the luminal vestibule, and however pantoprazole answers with Cys813 and Cys822.[19, 20]

Pharmacokinetic:

PPIs range in oral bioavailability from 30 to 90%. All are incredibly protein bound and keep a little volume of scattering (0.17-0.45 l/kg). Proton siphon inhibitors are handled through the P450 (CYP450) system, but huge differences are clear CYP450-2C19 besides, CYP450-3A4 are the fundamental substance structures related with their assimilation. Lansoprazole is processed by the two synthetic compounds, but absorption of esomeprazole, pantoprazole and omeprazole is predominately by CYP450-2C19. Rabeprazole is used by something almost identical cytochrome compounds, yet moreover goes through non-enzymatic assimilation, dodging the CYP450 way ways and allowing continued with processing despite the presence of experts that compete for the CYP450 compounds. These subtleties have huge implications for drug affiliations. These chemical frameworks compete with prescriptions and may raise unreasonable drug levels and their associated danger. Idle medicine metabolites outlined by the CYP450 synthetic compounds are released by the kidneys, with 0-1% of dynamic drug recoverable in the pee. In the event of kidney failure, this pharmacokinetic profile enables drug treatment without the need for dose adjustments. The PPIs, because of their wide protein limitation are not disposed of by hemodialysis; nevertheless, they genuinely require estimation change (reduced segment) in patients with outrageous liver illness. [21]

Pharmacodynamic:

Proton pump inhibitors diminish gastrointestinal destructive creation by controlling the H/K ATPase present on the secretory surface of gastric parietal epithelial cells. Low gastric Pl protonates the PPI, which switches it over totally to its dynamic design allowing covalent receptor confining and non-ferocious limitation of the siphon. Both basal and vivified destructive discharges decline following this

affiliation. The unique sort of these meds is handled by the liver into various inactive metabolites (hydroxy, dimethyl, sulfone particles), which are as such released by the kidneys. Fundamentally, disregarding the way that H/K ATPase is accessible on distal renal adjusted cells (intercalated cells), inactive metabolites essentially influence the siphon and seem, by all accounts, to be thoughtfully no effect on urinary pH or K+ release. In favor of this, omeprazole association to strong male subjects didn't change electrolyte balance or urinary PH. [22]

Association between PPIs and Kidney Diseases:

Proton-pump inhibitors (PPIs) are extensively seen for their feasibility and prosperity; in any case, kidney-related optional impacts, primarily extreme tubulointerstitial nephritis (ATIN), can every so often tangle their use. PPIs might conceivably induce hyponatremia, drug collaborations, and hypomagnesemia from gastrointestinal incidents. Also, emerging confirmation recommends that the usage of PPIs could add to the headway of continuous kidney disease (CKD). It is speculated that postponed ATIN, a sort of kidney disturbance, may progress to consistent tubulointerstitial nephritis, finally achieving CKD and potentially end-stage kidney disorder (ESKD). PPIs have been perceived as one of the principal wellsprings of medicine-activated ATIN all over the planet, particularly in patients who experience extraordinary kidney injury (AKI) during hospitalization and have biopsy-avowed ATIN. [24]

How PPIs May Cause Kidney Injury?

There is a hypothesis that inside the tubulointerstitial, proton-siphon inhibitors (PPIs) or possibly their metabolites could go through reactions that lead to their capacity as haptens. Then again, they may clearly quicken Safe framework microorganisms, achieving the intercession of extraordinary tubulointerstitial nephritis (ATIN). The testimony of proton siphon inhibitors and their metabolites in the tubulointerstitial causes an immune response which prompts interstitial bothering, Edema, and extreme interstitial nephritis (AIN) which causes extraordinary kidney injury (AKI) or interstitial fibrosis and barrel shaped rot; eventually framing into steady kidney ailment and end-stage renal contamination. [23, 24]



Dig 2: Physiology of ppi.

	Lansoprazole	Pantoprazole	Rabeprazole	Omeprazole	Esomeprazole
Dosage (mg/day)	15 - 30	40	20	20 - 40	20 - 40
Volume of distribution	0,39 I/kg	0.17 I/kg	N/A	0,34 - 0,37 I/kg	0,24 I/kg
Protein binding	97 - 99%	98%	95-98% -	96%	97%
Bioavailability	15 mg = 81% 30 mg = 91%	77%	52%	30 - 40%	90%
Metabolism by CYP450 enzymes in the liver.	CYP2C19 = CYP3A4	CYP2C19 > CYP3A4	CYP2C19 = CYP3A4 and nonenzymatic	CYP2C19 > CYP3A4	CYP2C19 > CYP3A4

Drug excretion	14 - 25% renal inactive metabolites, <1% parent drug in urine 67% bile.	71 - 82% renal inactive metabolites, nonactive drug in urine 18 - 20% fecal.	90% renal inactive metabolites, no active drug in urine 10% fecal.	77% renal inactive metabolites, "minimal" parent drug in urine 19% bile.	80% renal inactive metabolites, < 1% parent drug in urine.

Table 3: Proton Pump Inhibitor Characteristics [23, 24]



Graph no 1: Distribution of PPIs among the study population [25]



Fig 1: Percentage of incidence of acute kidney injury with each PPI [25]

Depicts the example and end-of-concentrate on biochemical potential gains of the patients who made AKI following PPI treatment. The conventional characteristics in our exploration office are according to the accompanying: blood urea; 10 to 40 mg/dl; serum creatinine; 0.4 to 1.2 mg/dl.

Discussion:

Despite the fact that the majority of the study's participants were between the ages of 31 and 50, the prevalence of acute kidney injury (AKI) was higher in the 51- to 70-year-old group, suggesting a connection between the onset of AKI and the physiological decline in renal capabilities. Nevertheless, a Dutch case series examination reveals no such age or orientation predisposition. Another case series from New Zealand showed the middle age to be 78 years (more ordinary in the more established). Pantoprazole was the most notable PPI obligated for the headway of AKI in the ongoing review, yet this could be in light of the fact that 82% of the audit people had supported pantoprazole, rather than the other PPIs. A concentrate by Sampathkumar K et al., similarly, showed that pantoprazole was the most caught PPI. Nevertheless, there are a couple of reports open, which report AKI with other PPIs. AKI is by and by remembered to be as a class effect of PPIs. The portion and length of PPI treatment didn't expect a basic part there of psyche of AKI. Similar results were seen in past assessments as well. The range of PPI treatment going before the headway of AKI changed from 7 to 21 days in the ongoing audit. The open composing shows a moved reach, from multi week to 90 days. The specific factor that is causing this negative effect is unclear. A couple of theories have been advanced. The AIN seen with PPIs is probably a safe reaction to the drug that is managed externally. Activation and verbalization of nuclear component kappa B have been entrapped in the pathogenesis. Moreover, it has been speculated that AKI could be discretionary to oxidative tension, which could relate to the usage of biomarkers like vanin-1. Urinary vanin-1 levels could behave like an impending biomarker to perceive AKI. Further,

The hypomagnesemia part associated with the use of PPIs could be one more clarification for progression of AKI and CKD, especially in the more settled people. [25]

PPI and kidney disease:

Altogether the two basic effects are AIN (Extraordinary interstitial nephritis), and TIN (Tubulointerstitial nephritis). AIN is a huge justification for extraordinary renal disillusionment coming about due to safe intervened tubulointerstitial injury. In AIN creatinine levels extended fundamentally and creatinine could potentiate hypoglycemia, hypertension, DVT, kidney stones, and migraines. TIN incorporates the immune mediated entrance of the renal tubules and interstation by combustible cells occurring in lessened renal capacity.

1. The ordinary ADRs of PPI are headache, infection, runs, stomach torture, weariness, and befuddlement. Long-term use of PPI can result in severe cases of these side effects, which can lead to gastroenteritis and other infections. As a result of these defilements, WBC remembers development for the body moreover, likewise long usage of PPI causes decreased stomach related acidic levels and can perpetually change the ph. Therefore, stomach related vegetation gets hurt and development in provocative cytokines and lymphocyte levels. This results in extra prospects thickening factors provoking coagulating. In this cycle thickening part IV (Calcium) moreover augments and these extended calcium levels bring about damage of kidneys by impeding renal adjusted cells managing mitochondrial injury.

2. In without Helicobacter pylori illness, the deferred use of PPIs produces parietal cell Hypertrophy and hyperplasia, achieving an effectively extended parietal cell mass. It is sensible that the parietal cell hyperplasia and hypertrophy saw with Omeprazole, Lansoprazole is a direct result of a trophic effect coming about due to the hypergastrinemia related with the hyperchlorhydria started by PPI. It similarly gives a physiological reason to the quickly return hyperchlorhydria temporarily related with suspension of treatment with PPI.

PPIs and Hypomagnesemia:

Some place in the scope of 2006 and 2008, a couple of described reports suggested that hypomagnesemia may be a generally inconspicuous disagreeable event related with PPI use. These basic discernments were trailed by a couple of case series, cross-sectional examinations, and two or three sidekick studies tending to various peoples (counting everyone, hospitalized patients, and in a general sense wiped out patients in the crisis unit). [26, 27, 28] Proof from this large number of studies suggests that PPI use relates to extended risk for hypomagnesemia, the bet is upgraded in patients correspondingly using diuretics, and the bet is extended with postponed term of PPI receptiveness. PPI use is moreover associated with extended risk for hypomagnesaemia in patients with CKD, counting those getting upkeep hemodialysis, yet confirmation in kidney migrate recipients stays meager. A couple of exact overviews and meta-examinations have since rehashed these disclosures of a basic connection between PPI use and risk for hypomagnesemia and suggested that the bet is furthermore extended in patients taking diuretics (either thiazide or circle diuretics) and was more expressed in those taking PPIs for expanded terms (≥1 year). In Walk 2011, the FDA gave a prescription security statement to enlighten the public that cure PPIs may "cause low serum magnesium levels (hypomagnesemia Mia) at whatever point taken for deferred time spans (generally speaking, longer than one year)" and that "magnesium smooth mentation alone didn't further foster low serum magnesium levels and the PPI should be stopped." [29, 30, 31]

PPIs and AKI:

Extreme kidney injury could be progressed by the quick abatement in kidney working achieved by tubulointerstitial pathologies. The assessment concerning the central explanations behind this condition

provoked the exposure of AIN, which a kidney biopsy constantly confirms. Gallium-67 scintigraphy is a technique that can be used to perceive AIN and extraordinary decay of the chambers in situations where biopsy isn't encouraged. [32, 33, 34] around 30% of the people who improve from AKI continue to have a raised possibility making CKD. A further horrible result of PPI use is hypomagnesemia. PPIs were associated with two times climb in the probability of having low magnesium levels, as shown by assessment of 9,818 individuals (95% CI: 1.36 to 2.93). The physiological cycle fundamental the abatement in magnesium, or Mg, levels achieved by PPIs isn't totally seen. Diminished pee centers gather that the stomach related framework is where magnesium utilization occurs. Studies suggest that CKD and low blood levels of magnesium (0.7 mmol/L) are connected. Long interstitial nephritis can at last achieve frustration of the kidneys and, in over-the-top conditions, CKD A sentinel case report by Ruffenach et al in 1992 was followed by a couple of story reports and different cross-sectional and accomplice focuses on uncovering a consistent connection between PPI utilizes what's more, risk for AIN. Based on the high prevalence of PPI use, a review suggested that this group of corrosive suppressants may be the primary cause of medication-induced AIN. Rich examinations by Clear et al are huge in that the analysts encouraged a settled case-control assessment and gave evidence for extended risk for AIN among current PPI clients versus a working comparator control past PPI clients, to some degree diminishing stresses over puzzling by sign (considering the way that the two get-togethers got PPIs) and giving confirmation to brevity between receptiveness to PPI and occasion of AIN that could update the case for causality. Other tremendous examinations uncovered extended risk for facility certification with AKI and AIN in the range of 120 days of PPI receptiveness. The affiliations between PPI use and peril for AIN and AKI have since been dependably imitated in various assessments. Taken together, the gathering of stars of confirmation unequivocally prescribes that PPI use should be considered as a putative blameworthy party in the evaluation of AKI and AIN, especially in the hospitalized setting. [35, 36]



Graph no 2: Age-wise distribution of the incidence of acute kidney injury (Age groups on the X-axis plotted against the percentage of subjects in the Y-axis). [25]

Pantoprazole was the most generally perceived cause among the PPIs causing AKI, followed by omeprazole moreover, rabeprazole. Lansoprazole was not found to cause AKI in two patients in whom it was embraced. The dispersal is depicted in the table.

PPIs and CKD:

During the past a surprisingly long time, huge confirmation has gathered from various gigantic sidekick studies suggesting that PPI use relates to extended risk for CKD results. Studies have dependably depicted a checked-on extension in risk with higher measurements and more deferred length of PPI treatment. Whether the occasion of AKI or AIN is driving the extended gamble for CKD results related with PPI use was analyzed in a concentrate by Xie et al. [37, 38, 39] The experts found that an enormous degree (close to half) of the connection between PPI use likewise, risk for CKD results isn't intervened by the occasion of interceding AKI or AIN, proposing a prompt pathway of indolent persevering kidney injury. The clinical meaning of this focus lies with the end that relying upon forerunner AKI to mindfulness of the bet of event CKD what's more, its development among PPI clients isn't isolated, satisfactory as a balance strategy. A couple of other observational examinations have since declared an unsurprising connection between PPI use and CKD brings about various partners. A couple meta-assessments have similarly maintained the connection between PPI use and extended bets for episode CKD, CKD development, and kidney disillusionment. 40, 41 how much confirmation woven together recommends that evasion techniques and effort zeroed in on reducing the bet for CKD development should address PPI use as a consistent ally of risk for the development and development of CKD. Determined kidney disorder (CKD) is the huge justification behind the early repulsiveness and mortality all over the planet with an overall regularity of 9.1% in 2017, achieving 35.8 million debilitation changed life years likewise, 1.2 million passing's (GBD Consistent Kidney Disease Participation, 2020). Risk factors influencing CKD are stunning, including bothersome lifestyles, strength, cardiovascular infection, diabetes mellitus, hypertension, and inappropriate prescription use. The creating medicine use, like NSAIDs, may in like manner add to the higher inescapability of CKD. There is confirmation that PPI use could impact kidney capacity and likewise achieve CKD. [42, 43]

Characteristics	Subgroups	AKI		CKD	
		Cases/N	Proportion/%	Cases/N	Proportion/%
Cases	All PPIs	3187	100	3457	100
	Omeprazole	561	17.6	166	4.8
	Pantoprazole	999	31.3	1196	34.6
	Lansoprazole	1014	31.8	1542	44.6
	Rabeprazole	55	1.7	28	0.8
	Esomeprazole	353	11.1	158	4.6
	Dex lansoprazole	205	6.4	367	10.6
PPI	One kind	2091	65.61	1673	48.39

	Two or more kinds	1096	34.39	1784	51.61
Age	< 18 years	24	0.8	10	0.3
	18-65 years	752	23.6	559	16.2
	65 years	882	27.7	419	12.1
	Unknown	1529	48	2469	71.4
Sex	Female	1038	32.6	892	25.8
	Male	971	30.5	695	20.1
	Unknown	1178	37	1870	54.1

Table 4: Characteristics of PPIs associated AKI and CKD cases from FAERS database. PPIs proton pump inhibitors, AKI acute kidney injury, and CKD chronic kidney disease. [44]



Graph no 3: Indications of PPIs associated AKI and CKD cases from FAERS database. PPIs proton pump inhibitors, AKI acute kidney injury, and CKD chronic kidney disease. [44]

PPIs are associated with acute interstitial nephritis:

AIN is one of the conflicting auxiliary impacts that PPIs are most frequently associated with. This insusceptible driven reaction is linked to both the interstation and the kidney tubules. Pollution, blood inconsistencies, resistant framework afflictions, and solutions all might potentially cause it. Tub tissue

cells are at first hurt, and thereafter a mononuclear combustible intrusion with a force of White platelets is seen. [45, 46, 47] the renal cortex could start to scare because of the intrusion spreading, which will moreover cause a reduction in kidney capacity. CKD with fibrosis of the interstitial space and decay of the cylindrical walls can occur in people with drug-induced AIN, provided that there is no improvement in side effects after stopping the prescribed medication and beginning the steroid. Isolated case reports of interstitial nephritis in patients taking PPIs have set off additional assessment. 8 Investigation has now confirmed this connection: patients who made serious kidney injury (AKI), including extreme interstitial nephritis (AIN), were something like twice as obligated to have taken PPIs appeared differently in relation to those without renal disease. New Zealand research has likewise reported that patients at this point using PPIs were four to different times bound to experience AIN stood out from non-clients. 5 Patients over 60 years old were the most frequently affected, with around 20 patients in this accomplice making AIN consistently per 100 000 patients taking PPIs. PPI-impelled AIN didn't have every one of the reserves of being segment dependent or associated with a range of treatment. This study declared no basic association between interstitial nephritis and past PPI use. [48, 49, 50]

Diagnosing intense interstitial nephritis in patients taking PPIs:

Remedies are the most notable justification for AIN; regardless, it could moreover be achieved by pollution or immunologic reaction. Patients with AIN customarily present with extreme renal disillusionment, what's more, a bunch of three of fever, rash and arthralgia. In any case, patients are likely to experience vague side effects like discomfort, anorexia, and a low-grade fever, which occur less frequently in PPI-induced AIN. The dipstick will typically display white cells and protein, but less frequently blood. Laboratory tests reveal severe impairment of renal function and occasionally eosinophilia.[51]

Early disclosure of AIN and the finishing of the causative drug is the best treatment. Patients related with having AIN should be suggested straightforwardly to nephrology: 40% of these patients will require dialysis. Although PPI-incited AIN may be less severe than AIN from other causes, recovery is typically slower. [52]

Renal injury	Drugs	Cases with renal injury/N	Renal injury cases with daily dose reported/n	WHO DDD/mg	Daily dose recommend end by drug label/mg	PPI daily dose/mg	
						Medium	IQR
AKI	Omeprazole	561	217	20	20-60	20	20-40
	Pantoprazole	999	320	40	40	40	40-40
	Lansoprazole	1014	404	30	15-60	30	30-40
	Rabeprazole	55	6	20	20-60	20	10-20
	Esomeprazole	353	198	30	20-40	20	20-40
	Dex lansoprazole	205	56	30	30-60	60	60-60
CKD	Omeprazole	166	42	20	20-60	20	20-40
	Pantoprazole	1196	332	40	40	40	40-40
	Lansoprazole	1542	662	30	15-60	30	30-40
	Rabeprazole	28	3	20	20-60	20	10-20
	Esomeprazole	158	51	30	20-40	40	20-40

	Dex lansoprazole	367	107	30	30-60	60	60-60

Table 5: Daily dose of PPIs from the FEARS database. PPIs proton pump inhibitors, AKI acute kidney injury, CKD chronic kidney disease, DDD defined daily dose IQR: interquartile range. [44]

Treatment:

Depending on the severity of the damage and the unidentified cause, proton siphon inhibitors (PPIs) and other corrosive lessening medications are used to treat kidney damage caused by stomach settling agents. Here is a framework of potential treatment moves close:

1. Halting or Change of Corrosive neutralizer Treatment:
a. Accepting kidney injury is thought or avowed to be associated with corrosive neutralizer use, the initial step is habitually to stop or change the usage of the trapped medication.
b. Clinical benefits providers could contemplate changing to elective destructive covering drugs, similar to receptor 2 receptor foes (H2 blockers), which have substitute instrument of movement and may address a lower danger of kidney injury.

2. Liquid Administration and Electrolyte Equilibrium:
A. Stay aware of acceptable hydration to work on renal perfusion and advance kidney capacity. Engage extended fluid confirmation aside from whenever contraindicated because of different infirmities (e.g., cardiovascular breakdown).
b. Check the levels of electrolytes like potassium, magnesium, and calcium, and if necessary, correct any abnormalities by changing the diet, taking supplements, or using drugs.

3. Renal Capacity Checking:
a. Screen renal capacity reliably through lab tests, similar to serum creatinine, evaluated glomerular filtration rate (eGFR), and urinalysis, to study kidney ability and perceive any movements for a really long time.
b. Change drug estimations or treatment systems considering changes in renal capacity and individual patient response.

4. Solid Thought and Aftereffect the board:
a. Continuously monitor for kidney injury-related side effects like electrolyte irregularities, corrosive base aggravations, and liquid overburden.
b. Address intricacies of kidney injury, similar to hypertension, Edema, and metabolic acidosis, through fitting pharmacological intercessions and lifestyle changes.

5. Treatment of Fundamental Conditions:
a. Identify and address any basic conditions or contributing factors that could exacerbate kidney damage, such as dryness, hypotension, volume exhaustion, and concurrent prescription use.
b. Supervise comorbidities that could impact renal capacity, similar to diabetes, hypertension, and resistant framework issues, through complete clinical chiefs and multidisciplinary care.

6. Renal Replacement Treatment (if central):
a. In serious occasions of extraordinary kidney injury (AKI) or steady kidney disease (CKD) with moderate diminishing in renal ability, renal replacement treatment (e.g., hemodialysis, peritoneal dialysis) may be supposed to help kidney capacity additionally, regulate complexities.
b. Begin renal replacing treatment in gathering with nephrology prepared experts and according to spread out rules and clinical signs.

7. Training and Follow-Up with Patients:
a. Show patients the meaning of medication adherence, lifestyle changes, and ordinary ensuing game plans for advancing seeing of kidney capacity.
b. Give information on dietary constraints, fluid confirmation ideas, and systems for preventing kidney injury rehash or development. It's vital for individualized treatment strategies considering the patient's clinical show, renal capacity, comorbidities, and response to treatment. Multidisciplinary collaboration among clinical benefits providers, including nephrologists, drug subject matter experts, and dietitians, is central for upgrading patient thought and results. Not surprisingly, talking with clinical benefits capable for altered clinical direction and treatment proposition specially crafted to individual patient necessities and conditions. [53, 54]

Diagnosis:

A couple of secondary effects should be noted while surveying for kidney disease. These include:

- Disorder
- Shortcoming or sleepiness that is beyond absurd
- Fluid upkeep causes extension in legs, lower legs, and feet
- Squeamishness that drives forward
- Lessened pee yield

Shortness of breath Specialists look for kidney disease light of blood and pee lab tests, imaging tests and at times a tissue test from the kidneys. Extremist interventions are expected with state-of-the-art kidney mischief and kidney frustration, including dialysis and kidney migration. Critical for people suspecting kidney issues to immediately search for clinical help.

Precautions:

Before taking any stomach-settling specialists or PPIs, you should chat with your clinical benefits provider. Especially if you are on dialysis, there may be restrictions on what you can take and how often you should take it. Specifically, you shouldn't self-treat your secondary effects with things bought from a drug store or pharmacy. Any therapy should consistently go in the direction of your clinical consideration provider.

Conclusion:

Stomach-settling specialists are non-professionally prescribed meds thusly used in tremendous aggregates by people without arrangement subsequently used absurdly and superfluously used corrosive neutralizers can harm the kidney. When compared to proton siphon inhibitors, H2 allergy medications have a smaller impact on the kidney. Proton siphon inhibitors are used in large quantities, and prolonged use of them increases the risk of CKD and AKI. Consequently, it's significantly improved to use ppi

whenever basic up to the assistance of aftereffects appear or in less total proton siphon inhibitor clinical consideration provider ought to be hopeful in embracing this medicine because of anticipated auxiliary impact.

Abbreviations:

AIN: Acute intestinal nephritis.
PPI: Proton pump inhibitor.
IV: Intravenous.
GERD: Gastroesophageal reflux disease.
CKD: Chronic kidney disease.
AKI: Acute kidney injury.
ATIN: Acute tubulointerstitial nephritis.
ESKD: End stage kidney disease.
OTC: Over the counter.

REFERENCE:

1. https://alchemlife.in/blogs/healthy-life/side-effects-of-antacids-overuse-can-cause- kidney-disease.

2. https://www.healthline.com/health/antacids medically reviewed by Dena Westphalen, PharmD — By Julia Haskins — Updated on April 25, 2023.

3. https://www.thehitavada.com/Encyc/2019/11/13/Print-warning-about-kidney-injury-on- antacids-Drug-Controller-asks-pharma.html.

4. https://my.clevelandclinic.org/health/drugs/23076-antacid

5. Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999 Jun; 57(6):855-70. [PubMed]

6. K D Tripathi, Essential of medical pharmacology, Eight Edition, 2019.

7. Thelin CS and Richter JE. Review article: the management of heartburn during pregnancy and lactation. Aliment PharmacolTher 2020; 51: 421–434. 2020/01/18. DOI:10.1111/apt.15611

8. Gupta D, Bhatia D, Dave V, et al. Salts of therapeutic agents: chemical, physicochemical, and biological considerations. Molecules (Basel, Switzerland) 2018; 23: 1719. DOI: 10.3390/molecules23071719.

9. IUPAC Gold book. Chemical species, https://goldbook.iupac.org/terms/view/ CT01038 (2019, accessed 16 January 2022).

10. Parakh R and Patil N. Anesthetic antacids: a review of its pharmacological properties and therapeutic efficacy. International Journal of Research in Medical Sciences 2018; 6: 383–393. DOI: 10.18203/2320- 6012.ijrms20180005.

11. Food and drug administration, department of health, education, and welfare. Antacid products for over the counter (OTC) human use, https://tile.loc.gov/storage-serv ices/service/ll/fedreg/fr039/fr039108/fr039 108.pdf#page=78 (1974, accessed 17 January 2022).

12. https://www.ncbi.nlm.nih.gov/books/NBK526049/

13. MacFarlane B. Management of gastroesophageal reflux disease in adults: a pharmacist's perspective. Integral Pharm Res Pract. 2018; 7:41-52. [PMC free article] [PubMed]

14. Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci. 2005 Dec; 27(6):432-5. [PubMed]

15. Robert M. Ward and Gregory L. Kearns. Proton Pump Inhibitors in Pediareics, Paediatr Drugs. PMCID: PMC3616221, 2013 Apr; 15(2): 119- 131.

16. Fujisaki H, Shibata H, Oketani K, et al. Effects of the proton pump inhibitor, E3810, on gastric secretion and gastric and duodenal ulcers or erosion in rats. Drug Invest 1991; 3: 328-332.

17. Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H＋, K＋) - ATPase by proton pump inhibitors. J Am ChemSoc 2004; 126:7800-7811.

18. Besancon M, Shin JM, Mercier F, et al. Membrane topology and omeprazole labeling of the gastric H＋, K＋- adenosine triphosphatase. Biochemistry 1993; 32:2345-2355.

19. Shin JM, Besancon M, Simon A, et al. The site of action of pantoprazole in the gastric H＋, K＋- ATPase.BiochimBiophysActa 1993; 1148:223-233.

20. Shin JM, Sachs G. Differences in binding properties of two proton pump inhibitors on the gastric H＋, K＋-ATPase in vivo. BiochemPharmacol 2004; 68:2117-2127

21. Brewster UC, Perazella MA. Acute kidney injury following proton pump inhibitor therapy.Kidney Int. 2007; 71:589-593

22. Howden CW, Reid JL. Omeprazole, a gastric proton pump inhibitor: lack of effect on renal handling of electrolytes and urinary acidification. Eur J Clin Pharmacol 1984; 26: 639-640.

23. Morschel, C. F., Mafra, D., Eduardo, J. C. C. (2018). The relationship between proton pump inhibitors and renal disease. Jornal Brasileiro de Nefrologia: órgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia, 40(3), 301-306.

24. Paueksakon, P., & Fogo, A. B. (2022). Do proton-pump inhibitors cause CKD and progression of CKD? COMMENTARY. Kidney360, 3(7), 1141-1143.6f

25. Avinash, Navin Patil, Sushil Kiran Kunder, O. Balaji, Amod Tilak, Ravi K. Sori, Raghavendra Rao, A Retrospective Study to Assess the Effect of Proton Pump Inhibitors on Renal Profile in a South Indian Hospital, Year: 2017 | Month: Apr | Volume: 11 | Issue: 04

26. Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia is induced by several proton-pump inhibitors. Ann Intern Med. 2009; 151(10):755-756.

27. Lindner G, Funk GC, Leichtle AB, et al. Impact of proton pump inhibitor use on magnesium homoeostasis: a cross-sectional study in a tertiary emergency department. Int J Clin Pract. 2014;68(11):1352-1357

28. Alhosaini M, Walter JS, Singh S, Dieter RS, Hsieh A, Leehey DJ. Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors. Am J Nephrol. 2014; 39(3):204-209.

29. Cegla J. The association between the uses of proton pump inhibitors and the risk

of hypomagnesemia: a systematic review and meta-analysis. Ann Clin BioChem. 2015; 52(2):302.

30. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015; 37(7):1237-1241.
31. Liao S, Gan L, Mei Z. Does the use of proton pump inhibitors increase the risk of hypomagnesemia: an updated systematic review and meta-analysis? Medicine. 2019; 98(13): e15011.
32. Torpey N, Barker T, Ross C. Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit. Nephrol Dial Transplant. 2004; 19(6):1441-1446.
33. Praga M, Gonzalez E. Acute interstitial nephritis. Kidney Int. 2010; 77(11):956-961.
34. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol.2010; 6(8):461-470.
35. Harmark L, van der Wiel HE, de Groot MC, van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol. 2007; 64(6):819-823.
36. Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. ClinNephrol. 2007; 68(2):65-72.
37. Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between protons pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018; 33(2):331-342.
38. Leonard CE, Freeman CP, Newcomb CW, et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. 2012;21(11):1155-1172.3
39. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016; 176(2):238-246.
40. Peng YC, Lin CL, Yeh HZ, Chang CS, Wu YL, Kao CH. Association between the use of proton pump inhibitors and the risk of ESRD in renal diseases: a population-based, case control study. Medicine. 2016; 95(15): e3363.
41. Arora P, Gupta A, Golzy M, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 2016;17(1):112
42. Wijarnpreecha K, Thongprayoon C, Chesdachai S, Panjawatanana P, Ungprasert P, Cheungpasitporn W. Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis. Dig Dis Sci. 2017; 62(10):2821-2827.
43. Klatte DCF, Gasparini A, Xu H, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702-710

44. Bin Wu1, Dan Li1,2, Ting Xu1,3*, Min Luo1, Zhiyao He1 & Yuwen Li1, Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system, (2021) 11:3690 |

45. Nast CC: Medication-induced interstitial nephritis in the 21st century. Adv Chronic KidneyDis. 2017, 24:72-9. 10.1053/j.ackd.2016.11.016

46. Perazella MA: Clinical approach to diagnosing acute and chronic tubulointerstitial disease. Adv Chronic Kidney Dis. 2017, 24:57-63. 10.1053/j.ackd.2016.08.003

47. Blank M-L, Parkin L, Paul C, et al. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int 2014; 86:837–44. http://dx.doi.org/10.1038/ki.2014.74

48. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case–control study. BMC Nephrol 2013; 14:150. http://dx.doi.org/10.1186/1471-2369-14-150

49. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ 2015; 3: E166–71. http://dx.doi.org/10.9778/cmajo.20140074

50. MEDSAFE. Proton pump inhibitors and interstitial nephritis. 2011. www.medsafe.govt.nz/profs/puarticles/protonpumpsept2011.htm (Accessed Jul 2016).

51. Praga M, Sevillano A, Auñón P, et al. Changes in etiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant 2015; 30:1472–9. http://dx.doi.org/10.1093/ndt/gfu326

52. Praga M, González E. Acute interstitial nephritis. Kidney Int 2010; 77:956–61. http://dx.doi.org/10.1038/ki.2010.89

53. KDIGO Work Group. (2012). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements, 3(1), 1-150. doi: 10.1038/kisup.2012.

54. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2012). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements, 3(1), 1-150. doi: 10.1038/kisup.2012.73. DBJHGGF